Its pipeline also includes Claudin 18.2-directed ADC BMS-986476 in phase 2 for gastrointestinal and pancreatic cancer, acquired as a result of its acquisition of Turning Point Therapeutics for $4. ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Compared to previously launched biosimilars, these therapeutics are gaining market ... This could be an important turning point for manufacturers, such as Boehringer Ingelheim and Pfizer, that ...

VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph ...

including notable advancements in Crispr Therapeutics AG’s pipeline and strategic partnerships. The company has shown promising progress with the Casgevy launch, evidenced by an increase in ...

Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025 ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline progress and anticipated 2025 milestones.

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline progress and anticipated 2025 milestones.

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew ...

New York, USA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Myocardial Infarction Clinical Trial Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive ...